{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-145022","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.421924+00:00","generated_at":"2026-06-25T22:36:13.021968+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvation Bio Q1 net loss $21.3M; pipeline focus on NUV-422, NUV-868, DDC","bullets":["Net loss $21.3M ($0.10 per share) vs $20.4M ($0.12) in Q1 2021.","Cash, cash equivalents and marketable securities $737.7M as of March 31, 2022.","R&D expenses $20.7M (up $4.8M YoY); G&A $7.5M (up $2.9M YoY).","On track to initiate Phase 1b combos and Phase 2 monotherapy for NUV-422 by end-2022; first patient dosed in NUV-868 Phase 1.","Deprioritized early-stage NUV-569 and A2A programs to allocate resources to NUV-422, NUV-868, and DDC program."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-145022","json":"https://secwatch.observer/filing/0001193125-22-145022.json","markdown":"https://secwatch.observer/filing/0001193125-22-145022.md","text":"https://secwatch.observer/filing/0001193125-22-145022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312522145022/0001193125-22-145022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312522145022/d293509d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:36:13.021968+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}